AWS
DNA icon

Atria Wealth Solutions’s Ginkgo Bioworks DNA Stock Holding History

Atria Wealth Solutions’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-723
Closed -$9.67K – 1955
2024
Q2 		$9.67K Sell
723
-94
-12% -$2.81K ﹤0.01% 1913
2024
Q1 		$37.9K Sell
817
-37
-4% -$1.92K ﹤0.01% 1930
2023
Q4 		$57.7K Buy
854
+28
+3% +$1.71K ﹤0.01% 1878
2023
Q3 		$59.8K Buy
826
+376
+84% +$30.1K ﹤0.01% 1810
2023
Q2 		$33.5K Buy
450
+100
+29% +$5.92K ﹤0.01% 1829
2023
Q1 		$18.6K Hold
350
– – ﹤0.01% 1838
2022
Q4 		$23.6K Buy
350
+28
+9% +$2.58K ﹤0.01% 1777
2022
Q3 		$40.2K Buy
322
+10
+3% +$1.19K ﹤0.01% 1708
2022
Q2 		$30K Buy
+312
New +$38.1K ﹤0.01% 1603

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atria Wealth Solutions's DNA Position: Q3 2024 in Review

Atria Wealth Solutions sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 723 shares — an estimated $9.67K sold.

Atria Wealth Solutions first reported a position in DNA in Q2 2022 and held it in 9 quarters. The position peaked at $59.8K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Atria Wealth Solutions reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Atria Wealth Solutions sold 723 Ginkgo Bioworks shares in Q3 2024, an estimated $9.67K.
  • Atria Wealth Solutions first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 9 quarters.
  • Atria Wealth Solutions's Ginkgo Bioworks position peaked at $59.8K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Atria Wealth Solutions's 13F filing for Q3 2024, filed 8 Nov 2024.